Talk:Alemtuzumab

vandalism
I think this article is vandalised once. It has no gangsters, and the diff is shown here: --BlakeCS 23:32, 24 February 2007 (UTC)

Sarcoid
- can cause sarcoid! JFW | T@lk  22:44, 23 June 2007 (UTC)

new study on MS
http://news.bbc.co.uk/2/hi/health/7680641.stm —Preceding unsigned comment added by 78.24.121.60 (talk) 06:09, 23 October 2008 (UTC)
 * Have used this to replace dead yahoo URL. - Rod57 (talk) 09:41, 25 October 2011 (UTC)

Campath being trialed for MS treatment
Campath is currently being trialed by cambridge university to treat MS. —Preceding unsigned comment added by 60.241.168.49 (talk) 05:07, 27 May 2009 (UTC)

Campath / license change controversy
This is mentioned twice, we really need to remove one. Any preference which should go? (I'd say the second mention, so the relicense is under the controversy). Unless anyone has any strong feeling either way I'll update Jtowler (talk) 07:21, 20 March 2013 (UTC)

Current (Sept 2014) availability outside US?
per a, shall we politely say, obsessive website [a]:

"Take the case of Sanofi's Lemtrada, a drug to treat multiple sclerosis that has been approved all over the world. Taken once a year, it alleviates the symptoms of the disease and delays the onset of paralysis. Although the drug has already been approved to treat leukemia-so it is safe-FDA did not approve the design of its Phase III study and refused to approve it last December. Sanofi resubmitted the drug with additional data in May, but no word yet from the FDA."

[a] http://www.realclearmarkets.com/articles/2014/09/23/the_fda_should_be_in_ebola-mode_all_the_time_101288.html

- The Wikipedia article says the drug's been withdrawn from sale pending relabeling and re-targetting (at higher prices). Anyone know whether it's still available and in which countries? Thanks wiki-ny-2007 (talk) 15:22, 27 September 2014 (UTC)

What change of dose and price from CLL to MS
What dose and price applied to CLL ? What value of sales for CLL ? What dose and price is now applied to MS ? - Rod57 (talk) 12:18, 17 October 2016 (UTC)
 * UK price for Lemtrada alemtuzumab 10 mg/mL, net price 1.2-mL vial = £7045.00 ~ £56,000 (for 5 + 3 infusions)- Rod57 (talk) 12:29, 17 October 2016 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified one external link on Alemtuzumab. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20110714063804/http://www.campath.com/hcp/AboutCampath.html to http://www.campath.com/hcp/AboutCampath.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 14:37, 30 June 2017 (UTC)

Querying status as a secondary treatment for MS - it is now very often first-line, and urgently recommended
article says "In MS it is generally only recommended if other treatments have not worked"

This was the case until a fiveish years ago, but there is a growing consensus that it should be first-line, because the earlier it and other 'highly effective-class' drugs are taken the greater the long-term benefits are.

The consensus doesn't seem to have been firmly established but might be an idea to add a clause to say

"In MS it is generally only recommended if other treatments have not worked, though numerous clinicians are arguing it should becomee a first-line therapy"

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501364/ 2A01:4B00:9D30:C000:D5F3:ED30:1712:1887 (talk) 08:50, 24 August 2023 (UTC)